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ABSTRACT: Fatty acid synthase (FASN), the sole protein
capable of de novo synthesis of free fatty acids, is
overexpressed in a wide variety of human cancers and is
associated with poor prognosis and aggressiveness of these
cancers. Orlistat, an FDA-approved drug for obesity treatment
that inhibits pancreatic lipases in the GI tract, also inhibits the
thioesterase (TE) of human FASN. The cocrystal structure of
TE with orlistat shows a pseudo TE dimer containing two
diﬀerent forms of orlistat in the active site, an intermediate that
is covalently bound to a serine residue (Ser2308) and a
hydrolyzed and inactivated product. In this study, we
attempted to understand the mechanism of TE-catalyzed orlistat hydrolysis by examining the role of the hexyl tail of the
covalently bound orlistat in water activation for hydrolysis using molecular dynamics simulations. We found that the hexyl tail of
the covalently bound orlistat undergoes a conformational transition, which is accompanied by destabilization of a hydrogen bond
between a hydroxyl moiety of orlistat and the catalytic His2481 of TE that in turn leads to an increased hydrogen bonding between
water molecules and His2481 and increased chance for water activation to hydrolyze the covalent bond between orlistat and
Ser2308. Thus, the conformation of the hexyl tail of orlistat plays an important role in orlistat hydrolysis. Strategies that stabilize
the hexyl tail may lead to the design of more potent irreversible inhibitors that target FASN and block TE activity with greater
endurance.
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■ INTRODUCTION
Fatty acid synthase (FASN) is the sole protein capable of de
novo synthesis of free fatty acids, most commonly 16-carbon
palmitate.1 Human FASN is overexpressed in a wide variety of
human cancers, and this overexpression correlates with higher
metastatic potential and poor prognosis.2 FASN overexpression
is also associated with increased resistance to cancer chemo-
therapeutics in breast and pancreatic cancer cells,3 indicating
that FASN is an attractive target for chemosensitization.
Human FASN consists of seven reaction domains: β-ketoacyl
synthase (KS), malonyl/acetyltransferase (MAT), β-hydrox-
yacyl dehydrase (DH), enoyl reductase (ER), β-ketoacyl
reductase (KR), acyl carrier protein (ACP), and thioesterase
(TE).4 De novo synthesis of fatty acids by FASN begins with
condensation of acetyl-CoA and malonyl-CoA, and continues
with elongation of the fatty acid chain, which is tethered to the
phosphopantetheine cofactor of ACP, via a repeating cycle that
adds two carbons each cycle.5 At the end of elongation, TE
cleaves the thioester bond between the fatty acid chain and the
phosphopantetheine of ACP and releases the free fatty acid.6
The TE domain of FASN is a member of the serine
hydrolase family, with the canonical Ser−His−Asp catalytic
triad. The hydrolysis of the thioester bond between fatty acid
and the phosphopantetheine of ACP involves the acceptance of
a hydrogen atom from His2481 by the sulfur atom of the
phosphopantetheine and the transfer of fatty acid chain to
Ser2308, forming an acyl-enzyme intermediate. Then the
catalytic nitrogen atom of His2481 hydrogen bonds and activates
a water molecule, which then undergoes nucleophilic attack of
the carbonyl carbon of the acyl-enzyme intermediate, and
releases the fatty acid from Ser2308 and regenerates Ser2308 and
His2481.7 Active site inhibitors of FASN TE including orlistat
can prevent the transfer of fatty acid from ACP to Ser2308 of TE.
Orlistat (Figure 1A) is an FDA-approved drug for obesity
treatment that inhibits pancreatic lipases in the gastrointestinal
tract, but has also been shown to inhibit TE of FASN.8 In
addition, orlistat sensitizes FASN-mediated drug resistance in
breast and pancreatic cancer cells;3 induces endoplasmic
reticulum stress,9 apoptosis,10 G1/S arrest in cancer cells;11
and inhibits angiogenesis and proliferation of endothelial
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cells,12 possibly by inhibiting FASN. Computational docking
analysis shows that orlistat binds to the ligand binding site in
TE,13 and the cocrystal structure of human FASN TE with
orlistat (ID: 2PX6) shows that orlistat is indeed present in the
active site of TE.14 Interestingly, in the same cocrystal structure,
orlistat exists both as a hydrolyzed product and as a covalently
bound intermediate (covalent-orlistat), in which the C1 carbon
of the β-lactone cyclic ester moiety of orlistat forms a covalent
bond with the active site Ser2308 (Figure 1A). In addition, the
hexyl tail of orlistat appears to adopt two diﬀerent
conformations in the covalent-orlistat and hydrolyzed product.
It was speculated that the hexyl tail of covalent-orlistat may
pack against His2481 and prevent the access and activation of a
water molecule needed for hydrolysis of the covalent bond
between orlistat and Ser2308.14 However, whether the
conformation transition of the hexyl tail occurs prior to the
catalysis, and whether and how the transition contributes to
catalysis is unknown.
In this study, we examined the potential role of the hexyl tail
in water activation for orlistat hydrolysis using molecular
dynamics (MD) simulations and found that the hexyl tail of
covalent-orlistat shifts from one conformation to another
within 35 ns simulations. However, the shift of the hexyl tail
does not increase the accessibility of water molecules to the
active site. Instead, this shift destabilizes a hydrogen bond
between the catalytic nitrogen atom of His2481 and the hydroxyl
moiety of covalent-orlistat, allowing a water molecule to be
activated via hydrogen bonding with His2481 in a proper
orientation for catalysis. Taken together, we conclude that the
hexyl tail in covalent-orlistat can shift from one conformation to
another, which plays an important role in orlistat hydrolysis by
TE.
■ EXPERIMENTAL METHODS
Orlistat Parameterization. Covalent-orlistat is a non-
natural residue, and therefore, parameters must be developed
for Molecular Mechanics (MM) calculations. To achieve this
goal, the coordinates of covalent-orlistat in TE were acquired
from the Protein Data Bank (ID: 2PX6). The charges for
covalent-orlistat are developed manually by a similar procedure
described by Cornell et al.15 Brieﬂy, covalent-orlistat and
Ser2308, as well as the adjacent tyrosine residues (Tyr2307 and
Tyr2309) on either side of Ser2308, were removed from the
enzyme and capped by retaining the peptide backbone from
Tyr2307 and Tyr2309, resulting in an N-terminal blocking cap that
consists of a −(CO−CH3) group and a C-terminal blocking
cap that consists of a −(NH−CH3) group (Supporting
Information, Figure S1A). The model system was optimized
at the B3LYP/6-31G* level of theory using the Quantum
Mechanics (QM) package Gaussian03. Bond lengths and angles
were optimized with dihedral angles between all heavy atoms
kept frozen, to ensure that the charge development of orlistat
reﬂects the charge distribution of the conformation seen in the
crystal structure. The electrostatic potential of the ligand was
then calculated with Gaussian03 using the HF/6-31G* level of
quantum mechanical theory. Next, the atomic charges of the
ligand were calculated in two steps by restrained electrostatic
potential (RESP) charge ﬁtting. In the ﬁrst step, the charges of
the caps, which sum to zero, were deﬁned and the charges for
the remainder of the atoms were calculated by RESP. In the
second step, charges for all atoms were ﬁxed except for methyl
(−CH3) and methylene (−CH2) hydrogens. Charge calcu-
lations were repeated to ensure that rotationally degenerate
atoms had equivalent charges. We intended to introduce as few
new parameters as possible, and analogy to the existing ﬀ03
atom types allowed us to deﬁne all missing values for covalent-
orlistat (see Supporting Information, Figure S2A and Table S1
for more information). Using UCSF Chimera,16 the caps were
then removed, and the orlistat-Ser2308 residue was reattached to
the enzyme by aligning the newly optimized molecule with the
original orlistat molecule, as seen previously by Pemble et al.14
Validation of Covalent-Orlistat Parameterization. To
verify that the MM parameters developed for covalent-orlistat
Figure 1. (A) Catalytic mechanism of orlistat hydrolysis by FASN TE.
The active site Ser2308 of TE nucleophilically attacks the C1 carbon of
the β-lactone moiety of orlistat to form a covalent bond between
Ser2308 and orlistat. Orlistat is then hydrolyzed and inactivated by TE.
The ω dihedral angle of the hexyl tail that deﬁnes conformations I and
II is depicted in red. (B) Alignment of average structures of covalent-
orlistat in conformations I (cyan) and II (magenta) from the ﬁrst
simulation and the hydrolyzed orlistat from the crystal structure
(orange). The Ser2308 portion of covalent-orlistat is shown in green,
and the hydrolyzed group in hydrolyzed orlistat is shown in light
green.
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agree with optimal geometries of the ω dihedral angle
determined by QM, a rotational dihedral scan with angles
diﬀering by 10 degrees was performed by both ab initio QM
and MM. The initial structure used for the dihedral angle scan
was prepared as follows: Covalent-orlistat, previously optimized
by Gaussian03 as mentioned above, and the two residues
adjacent to orlistat were removed from the rest of the enzyme
using Chimera. These tyrosine residues were modiﬁed to N-
terminal and C-terminal glycine residues to create a 3-mer
peptide containing covalent-orlistat (Supporting Information,
Figure S1B). To avoid electrostatic interaction between the N-
terminal amino group and the C-terminal carboxyl group, the
torsion angles of this 3-mer peptide were adjusted into an
extended conformation. The thirty-six rotamers of the ω
dihedral angle were created using Chimera. The single point ab
initio energy of each rotamer was calculated using Gaussian03
with the HF/6-31G* level of quantum mechanical theory. On
the MM side, the potential energy surface of the 3-mer peptide
was calculated using a nonperiodic vacuum model with the
sander module of AMBER. Each rotamer was minimized using
500 steps of steepest descent minimization. To ensure that the
conformation of each rotamer was not changed dramatically
during minimization, all atoms were weakly restrained by 25
kcal/mol/Å2 in Cartesian space using harmonic potential.
Molecular Modeling and MD Simulation. Missing loops
in the crystal structure of TE were modeled using ModLoop.17
Both the ﬀ03 parameters and hydrogen atoms were assigned to
the protein by the LeAP module of AMBER9. LeAP also added
TIP3 water molecules to solvate the structure in a box with a
distance of 8 Å between the wall and the closest atom in the
system, in addition to appropriate counterions to neutralize the
system. To calculate the long-range electrostatic interactions,
Particle Mesh Ewald was used. The nonbonded cutoﬀ was set
to 8.0 Å. Prior to performing a production MD simulation, the
system was equilibrated by a ﬁve-step protocol. First, the
solvated system was minimized by 500 steps of steepest descent
minimization followed by 500 steps of conjugate gradient
minimization with all protein−ligand atoms in the system being
restrained by 500 kcal/mol/Å2 in Cartesian space using
harmonic potential. Next, the energy of the whole system
was minimized by removing the restraints in place and 10 000
steps of steepest descent minimization followed by 15 000 steps
of conjugate gradient minimization. In the third step, the
system was heated with a restraint of 10 kcal/mol/Å2 to the
protein from 0 to 300 K gradually over a duration of 50 ps
controlled by Langevin dynamics with a collision frequency of 2
ps−1. The system was then equilibrated by constant pressure
dynamics simulation with a weak restraint of 10 kcal/mol/Å2 to
the protein with isotropic position scaling for 50 ps at 300 K.
The reference pressure was set as 1 bar, with a pressure
relaxation time of 1.0 ps. Finally, the system was further and
fully equilibrated for additional 60 ps at 300 K using constant
volume periodic boundaries, which was indicated by stable
structure, energies, and temperatures. This step was controlled
by Langevin dynamics with a collision frequency of 2 ps−1 and a
pressure relaxation time of 2 ps. The SHAKE procedure, which
weakly constrains bonds involving hydrogen atoms, was applied
to each step of the simulation. A total of 35 ns of production
MD were simulated using the same conditions as the
equilibration step. Two replicate simulations were performed
using the same initial structure and the same conditions. An
MD simulation with a truncated version of orlistat in which the
hexyl tail was virtually changed to a methyl group (Supporting
Information, Figure S1C) was also performed using the same
procedure described above. Additionally, the 3-mer peptide
containing covalent-orlistat was solvated and a total of 100 ns of
production MD were simulated using the above same
procedure. To examine the eﬀects of crystal packing on the
behavior of covalent-orlistat, a simulation for FASN TE chains
involving crystal contacts that may aﬀect the covalent-orlistat
binding mode was performed for 35 ns using the same
procedure described above, but equilibrated for 5 ns due to the
interchain movements.
Free Energy Calculations. To examine the free energy of
the covalent-orlistat ligand in each hexyl tail conformation, a
total of 50 snapshots over the course of each conformation in
each simulation were extracted from the simulation trajectories
of FASN TE. The free energy was calculated and decomposed
to covalent-orlistat residue using the MM_PBSA module of
AMBER by the equation PBtot = PBsol + gas, where PBsol =
PBsur + PBcal and gas = ELE + VDW + INT. PBsur is described
as the hydrophobic contributions to solvation free energy for
PB calculations, and PBcal is described as the reaction ﬁeld
energy calculated by PB. ELE is the nonbonded electrostatic
energy +1,4-electrostatic energy; VDW is the nonbonded van
der Waals energy +1,4-van der Waals energy; and INT is the
bond, angle, and dihedral energies. Additionally, to demonstrate
that the two conformations of covalent-orlistat are independ-
ent, distinct, and not a result of the inﬂuence from the protein,
two 100 ns trajectories were run for the 3-mer peptide, which is
composed of covalent-orlistat bonded to Ser ﬂanked by two Gly
residues, and the free energy decomposed to covalent-orlistat
was evaluated with a total of 50 snapshots in each conformation
using the MM_PBSA module.
Trajectory Analysis. The conformational transition
throughout the simulation was studied by analyzing the root-
mean-square deviation (RMSD) of covalent-orlistat and the ω
dihedral angle of the hexyl tail by ptraj. To monitor structural
stability, RMSD, root-mean-square ﬂuctuation (RMSF), and
secondary structure analysis were calculated by the ptraj
module of AMBER9. Water molecules in the active site of
the enzyme were determined using VMD by searching for the
water molecules within 3.5 Å of the catalytic nitrogen of His2481
and within 4.0 Å of the carbonyl carbon of covalent-orlistat that
the water molecule attacks. Hydrogen bonds between polar
atoms (N, O, S, F) in the system were examined using VMD
with the criteria of a donor−acceptor distance of 3.5 Å and an
angle cutoﬀ of 20 degrees. The donor−acceptor distance for
strong hydrogen bonding required for catalysis between water
molecules and His2481 was set to 3.0 Å. Finally, all statistical
calculations were performed using a two-tailed student’s t test
with Prism5 (GraphPad).
■ RESULTS
Covalent-Orlistat MM Parameter Veriﬁcation by
Quantum Mechanics. Figure 1A shows the structures of
free , covalent-, and hydrolyzed orlistat. The two conformations
adopted by the hexyl tails in covalent- and hydrolyzed orlistat in
TE in the crystal structure were assigned as conformations I
and II (Figure 1B), respectively, which are deﬁned by the ω
angle of the hexyl tail (Figure 1A,B). The hexyl tail of the
covalent-orlistat in conformation I has an ω angle of 337.97°
and is accommodated in pocket I or “short-chain pocket”
deﬁned by residues Thr2342, Tyr2343, and Tyr2462 of TE while the
hexyl tail of hydrolyzed orlistat in conformation II has an ω
angle of 139.54° and interacts with residues in pocket II or
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“shift pocket” deﬁned by residues Tyr2309, Tyr2343, and Ala2430 as
previously described.14
In order to examine the behavior of covalent-orlistat within
the active site of TE prior to hydrolysis using an MD simulation
approach, we ﬁrst parametrized the Ser2308 residue covalently
bound to orlistat using the well-established procedure from the
AMBER manual (see Experimental Methods and Supporting
Information).18 We next tested if our developed AMBER
parameters could reproduce the ab initio energy proﬁle for the
ω dihedral angle of the hexyl tail that deﬁnes conformation I
and II in the crystal structure by performing QM and MM
dihedral angle scans of a 3-mer peptide containing covalent-
orlistat attached to a Ser residue in the middle (Figure S1B). As
shown in Figure S2B, the MM method using the AMBER
parameters yielded an energy proﬁle that is very similar to the
curve generated by the ab initio method, with both proﬁles
showing two minima and two maxima. The two maxima
appeared at 8.2° and 248.2° in the ab initio curve and at 5.3°
and 246.8° in the MM curve, indicating a good agreement. The
two minima appeared at 158.2° and 308.2° in the ab initio
curve and at 158.4° and 306.4° in the MM curve, which not
only agree with each other very well but are similar to the ω
angles (139.54° and 337.97°) of the hexyl tail of covalent- and
hydrolyzed orlistat found in the crystal structure, respectively.
Interestingly, the QM energy barrier separating the two hexyl
tail conformations is 28.35 kcal/mol, which is considerably
high. Thus, we conclude that covalent-orlistat was parametrized
properly for MD simulations and that the hexyl tail of covalent-
orlistat may adopt two distinct conformations, as observed in
the crystal structure, before hydrolysis.
Two Distinct Conformations of the Hexyl Tail in
Covalent-Orlistat. To show that the hexyl tail of covalent-
orlistat can adopt both ω angle conformations observed in the
crystal structure without the inﬂuences from TE, and that these
conformations are energetically equivalent and independent
conformations, we performed a 100 ns MD simulation of the 3-
mer peptide containing covalent-orlistat (Supporting Informa-
tion, Figure S1B). As shown in Supporting Information, Figure
S2C, the ω dihedral angle begins at 303.79 ± 8.90° and changes
to 178.53 ± 14.59° at 12.55 ns. It then ﬂips back to 305.61 ±
9.68° at 52.09 ns. At 56.39 ns, the ω dihedral angle adopts
174.48 ± 15.44° again for the remainder of the simulation. The
conformations of the hexyl tail of covalent-orlistat with these
two major ω dihedral angles are similar to conformations I and
II as observed in the cocrystal structure and, thus, covalent-
orlistat without TE may adopt the same two conformations
prior to hydrolysis. In addition, the calculated free energies of
the 3-mer peptide containing covalent-orlistat in both
conformations are nearly identical with an energy of −329.61
± 7.55 kcal/mol in conformation I and −330.52 ± 7.81 kcal/
mol in conformation II. Thus, we conclude that, without
inﬂuence from the surrounding amino acid residues of TE, the
hexyl tail of covalent-orlistat can adopt two distinct but
energetically equivalent and interchangeable conformations that
are similar to the conformations seen in the cocrystal structure.
Compatibility of Covalent-Orlistat MM Parameters
with AMBER Force Field. To further determine whether the
developed parameters of covalent-orlistat are compatible with
the AMBER force ﬁeld, we examined MM minimizations of the
model system of TE in complex with covalent-orlistat in an
explicit water environment. The developed parameters
successfully minimized the initial structure with a convergence
criterion of 1.0 kcal mol−1 Å−1. During the 60 ps equilibration
period of the simulation, the RSMD of the whole protein was
stable and remained less than 1.5 Å. To conﬁrm that the
AMBER parameters of covalent-orlistat are suitable for MD
simulation studies, we monitored various parameters during 35
ns MD simulations. Both the temperature and energy remained
constant with little deviation during equilibration and
production MD runs of all three simulations. The RMSD of
the main chain atoms (RMSDTE) is less than 2.0 Å during the
entire simulation process (Figure 2A), which is consistently
observed in all three simulations. These ﬁndings indicate that
the overall protein structure is not disrupted or distorted
throughout the simulations. The secondary structure of each
residue is kept and agrees highly with the crystal structure.
More importantly, the simulated B-factors of the protein (B-
factorTE) and covalent-orlistat (B-factororlistat) are comparable to
the experimentally determined values14 (Supporting Informa-
tion, Figure S2D). Thus, we conclude that the parametrization
is appropriate and compatible with the current AMBER force
ﬁeld.
Conformational Transition of the Hexyl Tail in the
FASN TE Domain. The above studies showed that, in the
absence of the TE protein, covalent-orlistat in the 3-mer
peptide is able to adopt two diﬀerent conformations for the
hexyl tail, deﬁned by the ω dihedral angle, that are independent
and exchangeable. To determine if a conformational transition
can also occur to the hexyl tail of covalent-orlistat in its binding
pocket of the TE domain, and whether this transition has any
eﬀect on orlistat hydrolysis, we ﬁrst examined the conformation
Figure 2. (A) RMSD of TE (black) and covalent-orlistat (gray) during
the ﬁrst simulation. Times when the conformational transition begins
and completes are indicated. (B) ω dihedral angle of the hexyl tail of
covalent-orlistat in the orlistat-TE complex along the simulation.
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of the hexyl tail during the three independent 35 ns simulations
of the TE-covalent-orlistat complex.
The conformational transition of the hexyl tail can be
examined by two criteria: the RMSD and the ω dihedral angle
of the covalent-orlistat. We ﬁrst examined the RMSD value of
covalent-orlistat throughout each simulation and observed that
the hexyl tail remained in one conformation, as noted by a
stable RMSD, during the initial 3400 ps of the simulation until
transitioning to a second conformation, which was completed
at 18 250 ps when the RMSD of covalent-orlistat regained
stability (Figure 2A). Similar conformational transitions but at
diﬀerent times were also observed in two other independent
simulations with time spans of each conformation shown in
Table 1 and Figure S3A, B. In the Supporting Information,
Supplemental Video S1 shows a representative simulation of
the conformational transition of the hexyl tail.
We next determined if the two conformations observed in
these simulations are equivalent to and possibly represent
conformations I and II observed in the crystal structure, by
examining the ω dihedral angles throughout each simulation.
We found that there is a clear change in the ω angle between
the two stable states of covalent-orlistat (Figure 2B, Supporting
Information, S3A, B). In the three simulations, the average ω
angles ranges from 304.89 to 309.73° in stable state I and
172.68° to 176.32° in stable state II. Strikingly, the average ω
angles in stable state I and II is respectively similar to the ω
angles in conformation I (308.2°) and II (158.2°) determined
by the ab initio method (Supporting Information, Figure S2B).
Furthermore, the average ω angles are also similar to the ω
angles of the two conformations in the crystal structure. These
observations demonstrate that the two stable states of covalent-
orlistat seen in the simulations indeed correspond to
conformation I and II determined by ab initio method and
crystal structure. It is noteworthy that there is a brief reversion
of the ω angle from conformation II back to I and then a
second ω angle transition to conformation II (at ∼11 440−11
870 ps) was observed (Figure 2B). This is consistent with the ω
dihedral angle transition noted with the 3-mer peptide.
Next, the free energy of the covalent-orlistat within TE in
conformations I and II was calculated. Their free energies are
nearly equivalent, ranging from −131.60 ± 7.03 to −130.29 ±
6.21 kcal/mol in conformation I and −139.05 ± 6.26 to
−135.25 ± 7.19 kcal/mol in conformation II (Table 1),
indicating that conformation II is unlikely a simple relaxation of
conformation I. Together, these data show that the hexyl tail of
covalent-orlistat in TE has shifted from conformation I to II
during our simulations, which may resemble the conformational
transition during catalysis as suggested by the crystal structure.
Interactions of the Hexyl Tail with the Binding
Pockets. As discussed above, there are two pockets of residues
in the crystal structure that accommodate the hexyl tail of
covalent-orlistat in conformation I and hydrolyzed orlistat in
conformation II and they are called short-chain pocket and shift
pocket, respectively.14 The short-chain pocket (or pocket I as
we refer to) consists of residues Thr2342, Tyr2343, and Tyr2462,
and the shift pocket (or pocket II) consists of residues Tyr2309,
Tyr 2343, and Ala2430. To examine how the hexyl tail of covalent-
orlistat interacts with each set of residues during our
Table 1. Time Span of Conformation I and II, B Factor, and Free Energy for All Three Simulations
conformation ﬁrst second third crystal struct.
time span (ps)a I 0−3400 0−600 0−4000 N/A
II 18 250−35 000 4000−35 000 11 400−35 000 N/A
B-factorTE 43.8 ± 31.0b 25.2 ± 19.4b 38.64 ± 33.05b 36.6
B-factororlistat 77.1 69.2 83.4 60.2
Gcovalent‑orlistat (kcal/mol) I −130.29 ± 6.2b −131.05 ± 6.92b −131.60 ± 7.03b N/A
II −136.75 ± 5.47b −139.05 ± 6.86b −135.25 ± 7.19b N/A
aThe time span in which the hexyl tail adopted each conformation in each simulation was determined by examining the RMSD of orlistat in
conjunction with the ω angle transition. The time during which the transition was taking place was not included in our calculations. bStandard
deviation.
Figure 3. (A) Average structure (cyan) from the simulation when hexyl tail adopts conformation I is aligned with the crystal structure of covalent-
orlistat (pink). (B) The average structure (cyan) from the simulation when hexyl tail adopts conformation II is aligned with the crystal structure of
the hydrolyzed orlistat (pink). In both panels, orlistat, shown in gray with the hexyl tail in dark green, short-chain (Thr2342, Tyr 2343 and Tyr2462), and
shift pocket residues (Tyr2309, Tyr 2343, Ala2430) are depicted.
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simulations, the average structure of the protein with covalent-
orlistat in conformation I and II from a representative
simulation was aligned with the crystal structures of covalent-
orlistat and hydrolyzed orlistat, respectively. As shown in Figure
3A, the hexyl tail in conformation I clearly interacts intensively
with the pocket I residues, but not as much with pocket II
residues. In addition, pocket I residues in the simulated average
structure adopt similar conformations to the crystal structure.
However, the similarity of pocket II residues between the
simulated and crystal structures is not as high (Figure 3B).
Although Tyr2309 and Ala2430 can be aligned very well, it appears
that Tyr2343 adopts very diﬀerent conformation from the crystal
structure. In the crystal structure, Tyr2343 packs against the
hexyl tail of covalent-orlistat in conformation I, but it then
undergoes conformation transition and does not pack against
the hexyl tail of the hydrolyzed orlistat in conformation II. This
observation raised the possibility that the conformational
change of Tyr2343 may promote shifting of the hexyl tail. In
the simulations, however, the positioning of Tyr2343 changes
very little before and after the hexyl tail shifts and it continues
to pack against the hexyl tail of covalent-orlistat in
conformation II. This diﬀerence in the conformation of
Tyr2343 may be a result of the hydrolysis because we are
comparing the covalent-orlistat in the simulated average
structure with the hydrolyzed orlistat in the crystal structure.
This ﬁnding suggests that the conformation transition of
Tyr2343 may happen after the conformation transition of the
hexyl tail, and instead of promoting conformation transition of
the hexyl tail, it may facilitate the release of the hydrolyzed
orlistat.
Crystal Packing Favors the Hexyl Tail in Conformation
I. To understand whether crystal contacts have any eﬀects on
the conformation of the hexyl tail, multiple FASN TE chains
were created by crystal symmetry operation and were used to
perform another 35 ns MD simulation. Due to the crowdedness
eﬀect of the crystal lattice, residues Arg2352, Thr2356, Pro2357,
Gly2358, Cys2359, Glu2360, and Ala2361 in a diﬀerent chain (chain
B) directly interact with the covalent-orlistat in the current
chain (chain A). In addition, residues Tyr2347 and Thr2348 in
chain B may indirectly aﬀect hexyl tail conformation via
interacting with pocket I residues of chain A. RMSD and ω
angle of the covalent-orlistat in both subunits were examined.
Unlike our previous simulations containing only one FASN TE
chain, the hexyl tail of the covalent-orlistat molecule in chain A
was constrained in conformation I as indicated by the ω angle
(Figure 4A) and the low and stable RMSD (Figure 4B)
throughout the simulation. Interestingly, when examining the
covalent-orlistat molecules in chain B, the molecules behave
similarly to the covalent-orlistat molecules from our FASN TE
monomer simulations (Supporting Information, Figure S4).
Catalytically Critical Interactions at the Active Site.
We ﬁrst tested whether the shift of the hexyl tail may provide
access of water molecules to the TE active site proposed by
Pemble et al.14 by searching for water molecules that are ≤3.5 Å
to the catalytic nitrogen of histidine and ≤4.0 Å to the carbonyl
carbon atom of the covalent bond between orlistat and serine.19
Under this stringent condition, it appears that in both
conformations, the active site can be occupied by a water
molecule for a signiﬁcant amount of the time (Table 2). We
next determined whether the conformational transition aﬀects
the catalytically important salt bridge between Asp2338 and
His2481 7b (Figure 5A). The constant occupancy of this salt
bridge suggests that Asp2338 and His2481 couple tightly both
before and after conformational transition of the hexyl tail, and
its stability is not aﬀected by the conformational transition
(Figure 5B top panel, Table 2).
In addition to the salt bridge, we identiﬁed a hydrogen bond
between the catalytic nitrogen of His2481 and the hydroxyl
moiety of covalent-orlistat (Figure 5A). In contrast to the
occupancy of the Asp2338-His2481 salt bridge, the average
occupancy of this hydrogen bond over all three simulations
dropped signiﬁcantly from 55.8% in conformation I to 19.3% in
conformation II (Table 2, Figure 5B bottom panel). This agrees
with the increased distance between the catalytic nitrogen of
His2481 and the oxygen of the hydroxyl moiety of covalent-
orlistat when the hexyl tail adopts conformation II (Figure 5C,
Table 2). A similar increase in this distance was also observed
for the second and third simulations (Table 2). These results
indicate that in each simulation, the potential for orlistat and
His2481 to form a hydrogen bond is diminished following the
conformational transition. Therefore, the conformational
transition of the hexyl tail does not appear to aﬀect the salt
bridge but destabilizes the hydrogen bond between the catalytic
nitrogen of His2481 and the hydroxyl moiety of covalent-orlistat.
Activation of Catalytic Water Molecules. To further
understand how the conformational change of the hexyl tail
aﬀects catalysis, we next investigated the presence of potentially
activated water molecules in the active site of TE with orlistat in
both conformations using the following criteria. A catalytically
active water molecule (a) must strongly hydrogen bond with
His2481 (at a distance ≤3.0 Å); (b) must be ≤4.0 Å from the
carbonyl carbon atom of covalent-orlistat for nucleophilic
attack; and (c) must form an optimal catalytic orientation angle
of 105° ± 5° with the carbonyl carbon and the carbonyl oxygen
(Figure 6A).20 The average occupancy of water molecules that
meet all the three criteria is signiﬁcantly increased from 0.1% in
Figure 4. (A) ω angle of the hexyl tail in chain A during the simulation
involving crystal contacts. (B) RMSD of the covalent-orlistat in chain
A during the simulation involving crystal contacts.
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conformation I to 4.6% in conformation II (Table 2). This
observation suggests that when the hexyl tail is in conformation
I, a water molecule is unlikely to be catalytically activated and
the possibility of catalytic activation is signiﬁcantly increased
after the hexyl tail transitions to conformation II.
Table 2. Catalytically Important Interactions at the Active Site
conformations ﬁrst simulation second simulation third simulation
active site water occupancy (%) I 10.6 41.6 11.5
II 31.4 28.9 31.5
occupancy of Asp2338-His2481 salt bridge (%) I 100 98.4 100
II 82.2 99.6 99.9
occupancy orlistat-His2481 H-bond (%) I 55.6 63.3 48.5
II 6.0 25.9 25.9
orlistat-His2481 H-bond distance (Å) I 2.91 ± 0.21a 2.83 ± 0.13a 2.90 ± 0.18a
II 4.63 ± 0.99a 3.51 ± 0.65a 3.53 ± 0.70a
occupancy of H2O-His
2481 H-bond (%) I 14.1 8.3 17.0
II 57.8 36.9 25.6
occupancy of activated H2O molecule (%) I 0.3 0.0 0.0
II 5.7 4.1 4.1
aStandard deviation.
Figure 5. (A) Frame from the simulation showing the hydrogen bond
between His2481 and covalent-orlistat (magenta dashed line) and the
salt bridge between His2481 and Asp2338 (orange dashed line) when
covalent-orlistat adopts conformation I. Ser2308, Asp2338, and His2481
residues of TE are depicted in green, orange, and magenta,
respectively. (B) Occupancies of the salt bridge between Asp2338 and
His2481 (upper) and hydrogen bond between His2481 and hydroxyl
group of orlistat (lower) are shown along the simulation. (C) The
distance between the catalytic nitrogen atom of His2481 and the oxygen
atom of the hydroxyl group of covalent-orlistat along the simulation.
Figure 6. (A) Frame from the simulation showing an activated water
molecule in the active site. Hydrogen bonds are depicted by dashed
lines. C1 atom is highlighted by blue ball. (B) Correlation between the
occupancy of the orlistat-His2481 hydrogen bond and the occupancy of
activated water molecules in conformations I (blue points) and II (red
points) of the ﬁrst (◊), second (□), and third (Δ) simulation. (C)
The occupancy of the hydrogen bond between the truncated covalent-
orlistat and His2481 throughout the simulation.
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Correlation of Interactions in the Active Site. To
understand how the conformational transition may aﬀect the
chance of activation of a water molecule for catalysis, we
analyzed the ability of water molecules to form strong hydrogen
bonds (≤3.0 Å) with the catalytic nitrogen of His2481 before
and after the conformational transition of the hexyl tail. As
shown in Table 2, the occupancy of water molecules that can
strongly hydrogen bond with His2481 is increased from an
average of 11% in conformation I to 40% in conformation II (p
= 0.051).
Considering that there is a decrease in hydrogen bonding
between His2481 and the hydroxyl moiety of covalent-orlistat
and an increase in hydrogen bonding between His2481 and
water molecules, it is possible that these two events are
correlated. To test this possibility, we ﬁrst calculated the
occupancy of the hydrogen bond between His2481 and covalent-
orlistat when there is a water molecule in the active site that
satisﬁes all catalytic criteria, which was 0.7%, 0.8% and 1.0% in
the ﬁrst, second and third simulation, respectively. We then
performed a correlation analysis of the occupancy of the
hydrogen bond between His2481 and covalent-orlistat and the
occupancy of activated water molecules that satisfy all criteria
for a catalytic interaction in both conformations I and II. As
shown in Figure 6B, there is a clear trend of linear correlation
between these occupancies with a correlation coeﬃcient of
0.94, indicating that a water molecule is more likely to
catalytically interact with orlistat in the absence of the hydrogen
bond between covalent-orlistat and His2481. Together, the
above ﬁndings suggest that the hydrogen bond between
covalent-orlistat and His2481 may need to be abrogated to
successfully activate a catalytic water molecule.
Simulation of Truncated Orlistat Lacking the Hexyl
Tail. The above ﬁndings suggest that conformation I of the
hexyl tail may help stabilize the hydrogen bond between His2481
and covalent-orlistat. To test this possibility, we performed an
MD simulation analysis using a truncated covalent-orlistat
lacking the hexyl tail (Supporting Information, Figure S1C).
For this purpose, the hexyl tail of covalent-orlistat in the crystal
structure was virtually removed, parametrized, and simulated
similarly as described above for the intact orlistat. Figure 6C
shows that the hydrogen bond between His2481 and the
hydroxyl group of truncated covalent-orlistat was spontane-
ously and quickly disrupted at 8,190 ps. It remained in a
disrupted state and did not reform for any signiﬁcant amount of
time during the remainder of the simulation. Interestingly, the
occupancy of water molecules that can be potentially activated
before and after disruption of the hydrogen bond is 0.9% and
4.3%, respectively, which is consistent with the observations of
intact covalent-orlistat. Taken together with the results for
intact covalent-orlistat, we conclude that the hexyl tail in
conformation I likely stabilizes the hydrogen bond between
His2481 and covalent-orlistat, which prevents His2481 from
hydrogen bonding with and properly orienting and activating
a water molecule for catalysis in the active site.
■ DISCUSSION
The serine hydrolases are one of the largest classes of enzymes
and their catalytic mechanism has been studied since the
1960s.21 The action of the canonical Ser−His−Asp catalytic
triad has been extensively studied by experiments such as
mutagenesis combined with enzymatic assays,22 X-ray crystal-
lography,22,23 and NMR,24 as well as by QM/MM computa-
tions.25 The cleavage of the substrate involves two major steps.
First, the proton of the catalytic serine is abstracted by the
histidine. The Oγ of Ser nucleophilically attacks the carbonyl
carbon of the substrate to be hydrolyzed, forming a tetrahedral
oxyanion intermediate. This intermediate collapses shortly and
an acylenzyme is formed, which completes the acylation step of
the reaction. In the second step, a water molecule is activated
by deprotonation by the histidine, similar to the serine in the
acylation reaction. The activated water molecule attacks the
central carbonyl atom of the acylenzyme ester bond and forms
an anionic tetrahedral intermediate again. Similarly, this
intermediate collapses and results in the release of a carboxylic
acid and regeneration of the active site.
FASN TE shares the canonical catalytic triad with other
serine hydrolases.26 The hydrogen bond network at the
catalytic site is well-suited for the above catalytic mechanism
and is also similar to other serine hydrolases.26a,27 The special
feature of the cocrystal structure of human FASN TE with
orlistat (ID: 2PX6), however, is that orlistat is present in the
active site of TE in two states: a state covalently bound to the
enzyme indicating a reaction stopped at ﬁrst step and a state of
hydrolyzed product indicating a completed reaction. Interest-
ingly, the hexyl tail of orlistat in these two diﬀerent states
adopts two diﬀerent conformations (I and II). Whether the
hexyl tail shifts before or after the reaction completion and
whether and how the shift dominates the advancement to the
second step of the catalysis is not clear.
In this study, we modeled covalent-orlistat in a 3-mer peptide
and found that the two conformations in the crystal structure
are stable conformations and energetically equivalent as
determined using both QM and MM methods. This ﬁnding
suggests that the covalent-orlistat can adopt both conforma-
tions prior to hydrolysis. In addition, the ﬁnding that the hexyl
tail of covalent-orlistat in the 3-mer peptide can transit back
and forth freely between conformations I and II shown by MM
method further indicates that the conformational transition of
the hexyl tail may play a critical role in the advancement of the
catalysis to the second step. The fact that the two energetically
equivalent conformations captured in the crystal structure are
not equally reactive and the fact that the hexyl tail is not the site
for the hydrolysis to happen suggest that the hexyl tail may
exert its eﬀects on the protein in large scale. Although
combined quantum and molecular mechanical (QM/MM)
method can predict activation barriers and stationary structural
points for enzymatic reactions based on potential energy
surfaces, it requires predeﬁning up to only a few hundred QM
atoms within a system.28 This prerequisite limits the use of this
method to solve the problem in this study. Because the
conformational transition of the hexyl tail does not involve
bond-breaking or -forming, the MM approach can be used to
investigate the large scale eﬀect of the hexyl tail on the enzyme.
Our study shows that the hexyl tail in conformation I prevents
the activation of a water molecule because of a hydrogen bond
between the catalytic His2481 and the hydroxyl moiety of
orlistat. The conformation transition of the hexyl tail
destabilizes this hydrogen bond and leads to formation of a
hydrogen bond between His2481 and water molecules, allowing
the activation of a water molecule to hydrolyze the covalent
bond between orlistat and Ser2308. Therefore, the conformation
transition of the hexyl tail is critical and required for hydrolysis
of covalent-orlistat. Here, we applied distance criteria and the
Bürgi−Dunitz rule20 in identifying an “activated” water
molecule in the MM computational setting. Further studies
using QM/MM methods once an “activated” water molecule is
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identiﬁed by the MM method can investigate the bond
breaking process and the complete reaction pathways, which
may provide further support for the above ﬁndings by the MM
methods.
Another interesting observation from the complex structure
solved by Pemble et al. is the structure is that the result of
cocrystallization of TE and orlistat, not from a crystal soaking
experiment. During the lengthy cocrystallization process,
protein and ligand are coincubated in solution and can freely
react with each other without crystal packing restraints that are
present in crystal soaking experiment.14 Yet in this condition,
only some of orlistat is hydrolyzed, suggesting that the
nonhydrolyzed covalent-orlistat cannot be a result solely from
crystal packing. Rather, the crystal lattice may selectively pack
TE with covalent-orlistat in conformation I from solution in
one asymmetric unit and TE with hydrolyzed orlistat in
conformation II from solution in another asymmetric unit.
Once crystals are formed, the covalent-orlistat in conformation
I may not be able to transit to conformation II due to crystal
lattice restraint and therefore remain in nonhydrolyzed state.
Our simulation data agrees with the crystal structures and the
above mechanism. In all our water-explicit simulations
mimicking TE in solution without crystal contacts, the hexyl
tail of covalent-orlistat undergoes a transition from conforma-
tion I to II indicated by its RSMD and the ω angle, whereas the
subunit subjected to crystal packing is stabilized in
conformation I.
We observed that the ω angles of covalent-orlistat in the 3-
mer peptide can switch between conformation I and II freely.
We also observed that the ω angles of hexyl tail in TE can
switch between conformation I and II. However, most of the
time, covalent-orlistat in TE adopts conformation II, raising the
possibility that the binding of free TE in solution may stabilize
conformation II. This agrees with the calculated free energies of
covalent-orlistat in TE, which suggest conformation II is slightly
more favorable. The slight preference to conformation II in free
TE could be important for the conversion of orlistat, and it
ensures suﬃcient time in conformation II for hydrolysis, which
could be considerably quick compared with the conformation
transition, to happen. This conclusion is supported by the fact
that no covalent-orlistat in conformation II is captured in the
cocrystal structure. On the other hand, crystal contacts may
stabilize covalent-orlistat in conformation I as demonstrated by
our simulation when crystal packing from another chain exists.
This result further demonstrates that the two conformations of
covalent-orlistat are equivalent and the ﬁnal adopted con-
formation is susceptible to the surrounding environments from
the protein. Taking both the experimental and computational
observations into account, it is tempting to speculate that the
conformational transition of the hexyl tail may be a rate-limiting
step of orlistat hydrolysis.
We also showed that a hydrogen bond exists between the
catalytic His2481 residue and covalent-orlistat, which may inhibit
orlistat hydrolysis. It appears that in conformation I, the strong
interaction between the catalytic nitrogen atom of His2481 and
the hydroxyl moiety of covalent-orlistat greatly prevents water
molecules from hydrogen bonding with the same atom of
His2481 and from adopting the proper orientation for activation
and catalysis. When the hexyl tail transits from conformation I
to II, the hydrogen bond between His2481 and covalent-orlistat
is disrupted, which frees and enables His2481 to hydrogen bond
with and activate water molecules to attack the carbonyl carbon
of the orlistat-Ser2308 residue. In the cocrystal structure, the
distance between the catalytic nitrogen atom of His2481 and the
hydroxyl moiety of covalent-orlistat is 3.9 Å in conformation I,
representing a weak hydrogen bond between the two atoms. In
agreement with our simulation, this distance increased to 5.4 Å
in conformation II in the cocrystal structure. Although a
distance of 3.9 Å in conformation I indicates a weak hydrogen
bond, it should be considered that the crystal structure is a still
snapshot of a protein in solid state, which may not capture the
stronger hydrogen bonding event found in solution. Never-
theless, both the crystal structure and our simulation data
suggest stronger interactions between the catalytic nitrogen
atom of His2481 and the oxygen atom of the hydroxyl group of
covalent-orlistat in conformation I than in conformation II.
So we may conclude that the hexyl tail in conformation I
favors a stronger interaction between the catalytic nitrogen
atom of His2481 and the oxygen atom of the hydroxyl group of
covalent-orlistat, which prohibits hydrolysis. This is further
validated by the simulation of TE covalently bound to a
truncated orlistat lacking the long hexyl tail. The simulation
shows that the hydrogen bond between His2481 and the
hydroxyl moiety of truncated covalent-orlistat is quickly and
spontaneously disrupted, accompanied by an increase in
activated water molecules in the active site for hydrolysis.
Thus, the truncated orlistat may be more easily hydrolyzed than
the intact orlistat. These results are intuitive in that truncated
orlistat is structurally more closely related to the natural
substrates of FASN TE. Interestingly, it has been found
previously that ebelactone B, a β-lactone compound containing
an ethyl group in the same position as the hexyl tail of orlistat,
was more eﬀective in inhibiting FASN TE activity than
ebelactone A, which contains a methyl group,8 leading to the
speculation that this moiety may be important for stabilizing
the covalent bound ligand in the TE active site and protecting it
from hydrolysis.29 Our data supports this hypothesis and
provides a mechanistic model by demonstrating that the hexyl
tail in conformation I is needed to stabilize the hydrogen bond
that forms between His2481 and the hydroxyl moiety of orlistat,
which helps to prevent hydrolysis of the ligand. This
stabilization is lost when the hexyl tail is removed, or undergoes
conformation transition, likely leading to rapid hydrolysis
shortly thereafter. Orlistat is a reversible inhibitor of FASN,
although the conversion rate can be very slow. Considering that
FASN overexpression may cause an increased metastatic
potential, poorer prognosis, and resistance toward cancer
chemotherapeutics in a wide variety of human cancers,2,3
information from this study may help in the rational design of
more potent irreversible TE inhibitors for anticancer treatment.
By utilizing and stabilizing the hydrogen bond between the
ligand and His2481 and thereby inhibiting the activation of a
water molecule for catalysis, it would be possible to design or
discover inhibitors that covalently bond to TE and permanently
disable its function. Another strategy for next generation
compound design may be to use moieties that block the space
in the active site near His2481 that water molecules must occupy
for activation. This may be achievable, as it has previously been
shown in a similar case of inhibitors of E. coli TEM-1 β-
lactamase. Although β-lactamases have a diﬀerent catalytic triad
from that of TE, they contain an active site Ser. Inhibitors of β-
lactamase, such as penicillanic acid, inhibit the enzyme by
acetylation of this active site Ser.30 A modiﬁed form of
penicillanic acid, 6α-(hydroxymethyl) penicillanate, created by
incorporating a hydroxymethyl moiety designed to displace the
catalytic water molecule in the active site, resulted in a retarded
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rate of hydrolysis of the acyl-enzyme intermediate.31 The
mechanism of action was later conﬁrmed by X-ray crystallog-
raphy.31
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